Revisiting risankizumab: a newer biologic drug in dermatology.

INTRODUCTION

Risankizumab is an interleukin 23p19 inhibitor, approved by the USA Food and Drug Administration (FDA) for the management of moderate to severe plaque psoriasis. Apart from its utility in psoriasis, there are a number of other dermatologic conditions where risankizumab has demonstrated value. The aim of this narrative review is to describe the utility of risankizumab in psoriasis, as well as its implication in off-label dermatologic disorders.

EVIDENCE ACQUISITION

PubMed, Google Scholar, Scopus and ResearchGate were searched for scholarly articles related to risankizumab and its utility in dermatology using the search terms "Risankizumab" AND "Psoriasis" AND "other dermatological disorders."

EVIDENCE SYNTHESIS

Risankizumab is a valuable biologic agent for the management of psoriasis and psoriatic arthropathy. It has also been used successfully for other dermatologic disorders like hidradenitis suppurativa, pityriasis rubra pilaris and pyoderma gangrenosum.

CONCLUSIONS

Risankizumab's usage is not limited to psoriasis. Its benefit extends to many more dermatologic conditions. Besides, it has an acceptable safety profile.